What specific patient populations could benefit most from tumor-on-a-chip technology in improving personalized cancer treatment protocols?

Patients with brain tumors, gastrointestinal cancers, bladder cancer, and lung cancer are among the populations most likely to benefit from tumor-on-a-chip technology. Despite its promise, further research is needed to conclusively demonstrate improved outcomes and overcome challenges in clinical adoption.